Clincosm LogoSign in Get a demo

LBL-CISL-1: Hyper-CVAD Treatment in Lymphoblastic Lymphoma

Sponsor
Ajou University School of Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT01813344
Collaborator
(none)
50
Enrollment
1
Location

Study Details

Study Description

Brief Summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Time Perspective:
    Retrospective
    Official Title:
    The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
    Study Start Date :
    Jan 1, 2012
    Anticipated Primary Completion Date :
    Jun 1, 2013

    Outcome Measures

    Primary Outcome Measures

    1. Overall survival [3-year]

    2. Progression free survival [3-year]

    Secondary Outcome Measures

    1. Response Rate [24 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • age over 18 at diagnosis

    • Pathologically proven lymphoblastic lymphoma

    Exclusion Criteria:

    • proven HIV infection

    • pretreatment with other regimens

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ajou Universtiy School of Medicine Suwon Kyeonggi Korea, Republic of 443-721

    Sponsors and Collaborators

    • Ajou University School of Medicine

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Seong Hyun Jeong, Assistant professor, Ajou University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT01813344
    Other Study ID Numbers:
    • LBL-CISL-1
    First Posted:
    Mar 19, 2013
    Last Update Posted:
    Mar 19, 2013
    Last Verified:
    Mar 1, 2013
    Keywords provided by Seong Hyun Jeong, Assistant professor, Ajou University School of Medicine
    Adult lymphoblastic lymphoma
    Hyper-CVAD
    first-line treatment
    Additional relevant MeSH terms:
    Lymphoma
    Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Lymphoma, Non-Hodgkin

    Study Results

    No Results Posted as of Mar 19, 2013